A recent analysis found that product hopping for just five brand-name drugs costs the US healthcare system $4.7 billion annually.
The analysis from Matrix Global Advisors examined the effects...
A recent study found that switching from brand name to generic cholesterol medications has saved Medicare billions of dollars between 2014 and 2018, even as the number people on cholesterol-lowering...
Mylan and Biocon Biologics recently announced the US launch of biosimilar Semglee in vial and pre-filled pen presentations, to help control high blood pressure in pediatric patients with type 1...
After substantial review, NIH’s COVID-19 Treatment Guidelines Panel found that there were insufficient data to recommend either for or against the use of convalescent plasma for the treatment of...
Although remdesivir showed clinical benefit in patients with severe COVID-19, it showed little benefit on clinical status for moderately ill COVID-19 patients , a recent JAMA Network Open study...
Mylan recently announced the launch of the first FDA-approved therapeutically equivalent generic of Tecfidera capsules for the treatment of relapsing forms of multiple sclerosis (MS).
The launch came...
Roche and Regeneron recently announced a partnership to develop, manufacture, and distribute Regeneron’s investigational COVID-19 antibody combination.
For more coronavirus updates, visit...
HHS recently issued a third amendment to the Declaration under the Public Readiness and Emergency Preparedness Act (PREP Act) to expand access to lifesaving childhood vaccines during the COVID-19...
The Corona Accelerated R&D in Europe (CARE) recently launched to quicken COVID-19 therapy development leveraging both public and private companies.
For more coronavirus updates, visit...
HHS and the Department of Defense (DoD) recently announced that McKesson Corporation will be a central distributor of future COVID-19 vaccines and related supplies needed to administer the drug.
For...
A study recently published in JAMA Network Open found that nearly one-third of sole-source, off-patent, and off-exclusivity drug products saw major increases in drug prices over any calendar year.
In...
AstraZeneca recently announced an agreement with the European Commission (EC) to supply up to 400 million doses of its COVID-19 vaccine, AZD122.
For more coronavirus updates, visit our resource...
HHS and the Department of Defense (DoD) recently announced an agreement with Moderna to manufacture and deliver 100 million doses of the company’s COVID-19 vaccine candidate.
For more...
Pfizer recently announced a multi-year agreement with Gilead Sciences to manufacture and supply the company’s investigational COVID-19 treatment, remdesivir.
For more coronavirus updates, visit...
Patients with deductibles and coinsurance for brand medicines have significantly higher annual out-of-pocket costs than patients with fixed copays alone, according to a new analysis.
The analysis...
GSK and Sanofi reached an agreement with the UK government for the supply of up to 60 million doses of the company’s jointly developed COVID-19 vaccine.
For more coronavirus updates, visit...
Thermo Fisher Scientific and Lyell Immunopharma recently partnered to develop manufacturing processes create more effective cell therapies to benefit cancer patients.
The companies main goal is to...
GSK and CureVac recently announced a collaboration for the research, development, manufacturing, and commercialization of five mRNA-based vaccines and monoclonal antibodies (mAbs) targeting infectious...
Microsoft and C.H. Robinson recently partnered to transform supply chains of the future and enable real-time visibility for C.H. Robinson customers.
To meet the demands of evolving global supply...
Roche and Blueprint Medicines Corporation recently signed an agreement to provide exclusive rights to Roche for global co-development and commercialization of an investigational therapy for patients...
